Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
SABCS 2021
Watch our recent interview with Yeon Hee Park at #ASCO26 to hear about exploratory analysis from DESTINY-Breast09 of first-line trastuzumab deruxtecan + pertuzumab in HER2+ advanced or metastatic #BreastCancer 🧬 🩺
🔗
#Oncology #BCSM #TrialUpdate
DESTINY-Breast09: treatment duration & outcomes by best response in HER2+ mBC
Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, discusses an exploratory analysis from DESTINY-Breast09 ...
ow.ly
What do the results of the NorthStar study suggest about the future of local consolidation therapy in the treatment of EGFR-mutated #LungCancer?⭐
Find out from Saumil Ghandi, who explored the results with us at #ELCC26🫁
Watch:
#Oncology #TrialUpdate
Local consolidation and systemic therapy combinations in EGFR-mutated lung cancer
Saumil Ghandi, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, explores the future of local c...
ow.ly
How do surgical resection and #SBRT compare in patients with stage IV #NSCLC?🤔
@kushal_kriplani presents findings from a retrospective real-world outcomes study comparing the techniques at #ASCO26 🌎🫁
Watch:
#Oncology #LungCancer #LCSM #SurgOnc
Surgical resection versus SBRT in stage IV NSCLC: survival outcomes from real-world data
Kushal Kriplani, MBBS, SUNY Downstate Health Sciences University, Brooklyn, NY, discusses the results of a retrospective...
ow.ly
Chinmay Jani (@Jani_Chinmay) at #ASCO26 describes the design of a dose-escalation and cohort-expansion Phase I trial evaluating intratumoral oncolytic virus SVV-001 with ipi + nivo in high-grade #NeuroendocrineNeoplasms 💉🦠
Watch:
#Oncology #ImmunoOnc
Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs
Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, describes the design of a Phase I dose-escalatio...
ow.ly
In an interview at #ASCO26, Zhonglin Hao shares preliminary findings from an ongoing dose-escalation study of LB2102, a DLL3-targeted autologous #CAR-T cell therapy in patients with #SCLC or #LCNEC 💉🫁
Watch:
#Oncology #CART #LungCancer #LCSM @ASCO
Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
Zhonglin Hao, MD, PhD, University of Kentucky, Lexington, KY, presents preliminary findings from an ongoing Phase I ...
ow.ly
SABCS 2021
Watch our recent interview with Yeon Hee Park at #ASCO26 to hear about exploratory analysis from DESTINY-Breast09 of first-line trastuzumab deruxtecan + pertuzumab in HER2+ advanced or metastatic #BreastCancer 🧬 🩺
🔗
#Oncology #BCSM #TrialUpdate
DESTINY-Breast09: treatment duration & outcomes by best response in HER2+ mBC
Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, discusses an exploratory analysis from DESTINY-Breast09 ...
ow.ly
What do the results of the NorthStar study suggest about the future of local consolidation therapy in the treatment of EGFR-mutated #LungCancer?⭐
Find out from Saumil Ghandi, who explored the results with us at #ELCC26🫁
Watch:
#Oncology #TrialUpdate
Local consolidation and systemic therapy combinations in EGFR-mutated lung cancer
Saumil Ghandi, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, explores the future of local c...
ow.ly
How do surgical resection and #SBRT compare in patients with stage IV #NSCLC?🤔
@kushal_kriplani presents findings from a retrospective real-world outcomes study comparing the techniques at #ASCO26 🌎🫁
Watch:
#Oncology #LungCancer #LCSM #SurgOnc
Surgical resection versus SBRT in stage IV NSCLC: survival outcomes from real-world data
Kushal Kriplani, MBBS, SUNY Downstate Health Sciences University, Brooklyn, NY, discusses the results of a retrospective...
ow.ly
Chinmay Jani (@Jani_Chinmay) at #ASCO26 describes the design of a dose-escalation and cohort-expansion Phase I trial evaluating intratumoral oncolytic virus SVV-001 with ipi + nivo in high-grade #NeuroendocrineNeoplasms 💉🦠
Watch:
#Oncology #ImmunoOnc
Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs
Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, describes the design of a Phase I dose-escalatio...
ow.ly
In an interview at #ASCO26, Zhonglin Hao shares preliminary findings from an ongoing dose-escalation study of LB2102, a DLL3-targeted autologous #CAR-T cell therapy in patients with #SCLC or #LCNEC 💉🫁
Watch:
#Oncology #CART #LungCancer #LCSM @ASCO
Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
Zhonglin Hao, MD, PhD, University of Kentucky, Lexington, KY, presents preliminary findings from an ongoing Phase I ...
ow.ly
